Insider Purchases: Inside the Buy

Tag: Frederic Marsanne

Illustration showing everyday investors boarding a futuristic launch pad called Powerlaw that provides access to rockets labeled SpaceX, OpenAI, Kalshi, Stripe, Anthropic, Waymo, and Canva.

🛰️ The Venture Secondary Discount: Inside Powerlaw's Pre-IPO Liquidity Arbitrage

Powerlaw isn't simply another investment company—it's a gateway into some of the world's most valuable private technology businesses. With insider buying near NAV and holdings including SpaceX, OpenAI, Kalshi, Stripe and Anthropic, investors must answer one key question: are they buying today's NAV, or tomorrow's?

Read entire article

Tags: BenjaminBlack, buy or sell PWRL, closed end fund, ClosedEndFunds, featured-diversify, Frédéric Marsanne, FUNanc1al, growth investing, hub-diversify, hub-insiders, insider buying, InsiderBuying, Kalshi, late stage startups, MikeDinsdale, NAV discount, net asset value, NetAssetValue, OpenAI, OpenAI investment, Powerlaw, PowerlawCorp, private equity, PWRL, risks buying PWRL, SpaceX IPO, SpaceX stock, SpaceXIPO, SPCX, technology investing, venture capital, venture secondary market, VentureCapital, why buy PWRL
Illustration depicting Abbott Laboratories as a futuristic healthcare city with FreeStyle Libre glucose sensors, cancer diagnostics trains labeled Cologuard and Cancerguard, happy doctors and patients, and a giant Dividend King castle.

🩺 Abbott Laboratories (ABT) Stock Analysis: Can a Dividend King Turn Exact Sciences Into Its Next Growth Engine?

Abbott Laboratories may not be flashy, but the healthcare giant combines insider buying, a growing oncology diagnostics platform, the dominant FreeStyle Libre franchise, and more than a century of dividend payments. With shares trading near 16x forward earnings, investors may be looking at a classic Growth at a Reasonable Price opportunity.

Read entire article

Tags: Abbott Laboratories, Abbott stock analysis, AbbottLaboratories, ABT, ABT stock, buy or sell ABT, cancer diagnostics, Cologuard, diagnostics stocks, dividend growth investing, Dividend King stocks, DividendKings, Exact Sciences acquisition, ExactSciences, featured-insiders, Frédéric Marsanne, FreeStyle Libre, FreeStyleLibre, FUNanc1al, GARP investing, healthcare innovation, healthcare stocks, hub-insiders, insider buying, InsiderBuying, medical devices, MedicalDevices, oncology investing, PhilipBoudreau, risks buying ABT, value investing, ValueInvesting, why buy ABT
Colorful cartoon illustration showing giant business-suited avocados and executives pouring cash into a giant bowl of guacamole labeled AVO while farms, trucks, blueberries, and a Calavo factory operate in the background.

🥑 Mission Produce (AVO) Stock Analysis: Why Insiders Just Bought $7.9 Million of Stock

Mission Produce's directors recently deployed nearly $7.9 million of personal capital into AVO shares. Combined with the Calavo acquisition, a fresh $100 million buyback, and a move into higher-margin prepared foods, the avocado giant may be entering a new chapter.

Read entire article

Tags: Agribusiness, agriculture stocks, AVO, AVO stock, avocado stocks, BruceTaylor, buy or sell AVO, buyback stocks, Calavo Growers, CalavoGrowers, CarpeDiem, consumer staples, ConsumerStaples, featured-diversify, featured-insiders, food distribution, food stocks, Frédéric Marsanne, FUNanc1al, guacamole, hub-diversify, hub-insiders, insider buying, InsiderBuying, JayPack, JohnPawlowski, Mission Produce, Mission Produce stock analysis, MissionProduce, prepared foods, risks buying AVO, ShortSqueeze, small cap stocks, stock market, value investing, ValueInvesting, why buy AVO